Wall Street’s November opened with a sharp break for technology shares. On November 3, the Nasdaq 100 slid into a correction, falling 10.4% below its October 6 peak. Economist David Rosenberg of Rosenberg Research called a correction “probably inevitable.” Two days later, the slide turned into a rout that hit every major index.
The Worst Day for the Nasdaq in 19 Months
On November 5, the Nasdaq Composite fell 5.52% to 24,315.00, its deepest one-day drop in 19 months. The move confirmed a correction, leaving the index more than 10% below its October 6 record close. The S&P 500 lost 4.36% to 7,353.73, erasing about $3 trillion of market value, and the Dow Jones Industrial Average fell 3.44% to 51,523.06.
Chip stocks took the worst of it, with the Philadelphia Semiconductor index dropping more than 12%. Fears of tighter AI regulation after Democrats won control of Congress drove the selling. Melissa Brown, global head of investment decision research at SimCorp, said investors appeared to be recognizing that some newly elected members of Congress and governors want to slow the pace of AI development. Jed Ellerbroek, a portfolio manager at Argent Capital Management, called it “the capitulation phase for the data center capex beneficiary stocks, especially the semiconductors.”
Investors looking for names the selloff pushed down can start with our list of oversold AI stocks that Wall Street analysts see rising 50% or more.
Rate-Hike Bets Add Pressure
Interest rates gave the market a second problem. The Federal Reserve raised rates in September, and Fed officials Beth Hammack of the Cleveland Fed and Thomas Barkin of the Richmond Fed hinted that more hikes could follow. Traders were already betting on another increase in December when the selloff hit.
Hotter-than-expected inflation data then strengthened those bets. By November 16, markets were fully pricing in a December hike, according to the CME FedWatch tool. Fed Chair Kevin Warsh was scheduled to speak that day, and minutes of the central bank’s October meeting were due on November 18.
For readers who want the other end of the rating scale, our ranking of NYSE stocks with huge upside potential covers the names analysts like.
Rates were not the only pressure on technology shares. Ipek Ozkardeskaya, senior analyst at Swissquote, said investors who buy into a major AI public offering may sell their existing tech holdings to pay for it, which adds to the selling in a market that is already falling.

A person with a cell phone who is looking for new stocks
Our Methodology
To compile this list, we reviewed analyst rating downgrades and price target cuts announced on Wednesday, November 18, 2026. We have ranked these stocks in ascending order of their average upside potential, as of November 18.
At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).
Analysts Turned Bearish on These 10 Stocks on Wednesday
10. New York Times (NYSE:NYT)
Average Upside Potential: 7%
Citi analyst Jason Bazinet moved The New York Times to Neutral from Buy on November 18 and cut his price target to $76 from $85. He pointed to deteriorating near-term engagement that could slow subscription growth, and said the near-term balance of risk and reward looks less attractive. He remains confident in the long term.
The company sells subscriptions to its journalism and its digital products, so subscriber growth carries most of the story. In the third quarter of 2026, which the company reported on November 4, it added about 420,000 net digital-only subscribers and ended with 13.76 million total subscribers. Digital-only average revenue per user rose 1.4% to $9.93.
Bazinet’s note names four measures of reader behavior: app downloads, active users, how often readers visit and how long they stay. He described all four as deteriorating, which means his concern rests on how readers use the product rather than on the subscriber total already reported. His change is about the pace of the next few quarters rather than the business’s long-term position. The shares trade at 22.49 times forward earnings.
9. Insulet (NASDAQ:PODD)
Average Upside Potential: 26%
Stifel analyst Jonathan Block cut Insulet to Hold from Buy on November 18 and lowered his price target to $165 from $180. His note cited weaker momentum in the United States.
Insulet makes the Omnipod, an insulin delivery system for people with diabetes. In the third quarter of 2026, revenue rose 19.2% to $842.0 million, with US Omnipod revenue up 14.7% and international Omnipod revenue up 31.7%. The company reported those results on November 4, so Stifel’s change in view came after both regions had grown at double-digit rates.
Block’s note centers on the larger of those two businesses, the American one. He also expects competition from other tubeless insulin pumps to compress the multiple investors will pay for the stock. The slower-growing segment is therefore the one carrying the most weight in his argument, and his argument rests on direction rather than current size. That left the company growing at a double-digit rate in every region it reports, with Stifel’s cut tied to one of them. Readers following the group can find more names in our list of healthcare stocks to buy.
8. Eaton (NYSE:ETN)
Average Upside Potential: 37%
Erste Group analyst Hans Engel cut Eaton to Hold from Buy on November 18, with no price target attached. He focused on the balance sheet, where acquisition-driven growth has pushed up the company’s debt.
Eaton makes electrical equipment that distributes and protects power in buildings, factories and data centers. In the third quarter of 2026, sales rose 28% to $8.9 billion, with organic growth of 19%. Segment margins hit a record 25.3%, electrical backlog grew 46%, and the company agreed to buy COL Group. Eaton also raised its organic growth guidance.
Debt is the sticking point. Engel noted that acquisitions had roughly doubled long-term liabilities. Eaton reported those results on November 3, and the same quarter included the COL Group agreement, so the acquisitions behind Engel’s debt concern sit alongside evidence of demand rather than against it. Whether that backlog turns into lasting profit is the subject of our analysis of how Eaton’s electrical backlog could translate into earnings power. The stock trades at 21.21 times forward earnings. Erste Group attached no price target to its call, so the rating change itself is the message.
7. GE Vernova (NYSE:GEV)
Average Upside Potential: 43%
Erste Group analyst Hans Engel cut GE Vernova to Hold from Buy on November 18 and attached no price target. He expects slower order growth next year and a slow recovery in wind, and he considers the valuation high for a company whose revenue growth is slowing. He still calls it a global leader in grid modernization, so his concern is price and pace rather than position.
GE Vernova builds gas turbines, wind turbines and electrical equipment for power grids. In the third quarter of 2026, reported on October 28, orders reached $29.3 billion, up 96% organically, and backlog rose to $197 billion. The company raised its 2026 guidance and said it expects backlog above $200 billion in the fourth quarter.
Those numbers set a high bar for the order growth Engel doubts. His view is a forecast for next year, not a comment on the results already reported. GE Vernova trades at 30.76 times forward earnings. Another view of how the company’s order book relates to its price is in our look at a $176 billion backlog meeting a 66x price tag.
6. Freeport-McMoRan (NYSE:FCX)
Average Upside Potential: 54%
Erste Group cut Freeport-McMoRan to Hold from Buy on November 18, without a price target. Erste cited falling copper and gold sales in 2026 while Indonesian output ramps up only gradually, and it expects the copper price to move sideways.
Freeport-McMoRan mines copper and gold, including at Grasberg in Indonesia. In the third quarter of 2026, reported on October 27, copper sales were 749 million pounds against 977 million a year earlier, and gold sales were 105 thousand ounces against 336 thousand. Sharply higher realized copper prices masked the drop, so revenues and earnings per share still rose from a year earlier.
The company expects about 3.0 billion pounds of copper in 2026 and says the Grasberg ramp-up should bring significant growth in 2027 and 2028. That timeline is what Erste’s volume argument runs against, because the growth it describes sits in years that have not begun. The call therefore rests on the timing of that growth, not on its existence. The stock trades at 12.03 times forward earnings. Our piece on whether copper tightness can outrun rising costs examines the cost side.
5. Nvidia (NASDAQ:NVDA)
Average Upside Potential: 60%
Summit Insights analyst Kinngai Chan cut Nvidia to Hold from Buy on November 18, with no price target, the day after the company reported its results on November 17. He pointed to the uncertainty that a leadership change creates for its product roadmap.
Jensen Huang is no longer chief executive, and Chief Financial Officer Colette Kress is serving as interim CEO as well as CFO. Nvidia makes the chips that power AI data centers, and the results Chan weighed were large. In the third quarter of fiscal 2027, revenue was $115.8 billion, up 103%, and Data Center revenue was $107.6 billion. The company said it expects fourth-quarter revenue of $130.0 billion.
The two facts pull in opposite directions: growth above 100% on one side and a leadership gap on the other. That is why the call turns on who runs the company rather than on demand for its chips. Chan’s rating change leaves the stock without a price target from Summit Insights. Nvidia trades at 9.26 times forward earnings. Our analysis of whether Nvidia is priced as if growth will stop covers the valuation question in depth.
4. Alnylam (NASDAQ:ALNY)
Average Upside Potential: 86%
JPMorgan analyst Jessica Fye cut her price target on Alnylam to $254 from $369 on November 18 and kept an Overweight rating. After reviewing the company’s model, she lowered her Amvuttra revenue forecasts for every year from 2026 through 2030.
Alnylam is a biopharmaceutical company and a pioneer of RNA interference therapies. Its main drug, Amvuttra, is sold for ATTR-CM, a heart condition. In the third quarter of 2026, reported on October 29, global net product revenues reached $1.29 billion, and Amvuttra revenue grew 65% from a year earlier.
The company also kept its 2026 outlook, with revenue from its transthyretin (TTR) products expected between $4.20 billion and $4.50 billion. Fye’s lower forecasts run against the growth path for the drug that supplies most of those sales. Her target is a December 2027 price objective. The release also said Alnylam expanded enrollment in its TRITON-CM Phase 3 study of nucresiran, designed to support an expected ATTR-CM launch, and plans to start a pivotal study of brezosiran in Huntington’s disease. Readers following the group can find more names in our list of biotech stocks that billionaires own.
3. Strategy (NASDAQ:MSTR)
Average Upside Potential: 143%
Monness Crespi & Hardt cut Strategy to Sell from Neutral on November 18 and set a price target of $65. The firm cited weak Bitcoin prices and the company’s leverage and dilution, which it said could erode the premium investors pay for its Bitcoin holdings.
Strategy is built around the Bitcoin it holds on its balance sheet, and its results swing with that asset. The company reported its third-quarter 2026 results on October 29. Operating income in the period was $20.91 billion, almost entirely a $20.91 billion gain on digital assets, so the line says more about Bitcoin’s price than about an operating business. Bitcoin’s price therefore drives both the gain and the worry. Net income was $19.53 billion, or $44.75 per diluted share. Preferred dividends took $419.6 million out of that before earnings reached common shareholders.
Those preferred payments belong to the leverage question the call raises. Monness Crespi & Hardt had rated the stock Neutral before the call, so the move takes it from the middle of the rating scale to the bottom. We took up that tension in our piece on whether the leverage is still worth the complexity.
2. Summit Therapeutics (NASDAQ:SMMT)
Average Upside Potential: 178%
Bernstein analyst Jeffrey Walch cut Summit Therapeutics to Underperform from Market Perform on November 18 and lowered his price target to $8.30 from $11.90. He listed three mistakes in the company’s dealings with the FDA over its lung cancer drug and reduced the probability of success for every ongoing Phase 3 trial by 25%.
Summit develops ivonescimab, a cancer therapy. On November 15, the company said the FDA had issued a Complete Response Letter on its application to treat EGFR-mutated non-small cell lung cancer after prior therapy. The agency said substantial evidence of effectiveness was not established without a statistically significant overall survival benefit, and that a progression-free survival benefit alone did not support a positive benefit-risk profile.
Walch’s three criticisms concern the HARMONi trial: that Summit did not follow ICH E17 guidance, with 93% of progression-free survival events in patients from China; that it cut the data too early on four occasions; and that it could have been more open about regional risk. Summit pointed to five positive Phase III studies and to ongoing trials, including HARMONi-3 and HARMONi-7. Our story on the HARMONi-2 overall-survival result Akeso reported against pembrolizumab covers the survival question.
1. Cue Biopharma (NASDAQ:CUE)
Average Upside Potential: 1342%
B.Riley cut its price target on Cue Biopharma to $25 from $83 on November 18 and kept a Buy rating. The firm said the multi-year financing path is the largest driver of the cut.
Cue Biopharma is a clinical-stage drug developer focused on immune disorders, led by its anti-IgE candidate CUE-221. In the third quarter of 2026, reported on November 16, the company posted a net loss of $50.0 million, a sharp increase from the same period a year earlier. Cash and cash equivalents were $57.9 million at September 30, 2026, a figure that frames the financing question B.Riley raised.
The clinical data are the other side of the call. In patients with high baseline IgE who received 4 mg/kg of CUE-221 in the Phase 2 chronic spontaneous urticaria study, 78% reached complete hive resolution at week 12, against 0% on placebo. At week 28, 12 weeks after the last dose, the benefit persisted in the 4 mg/kg group. The company has also begun first-in-human dosing of CUE-401 in a Phase 1 trial. Our earlier look at whether longer relief could set Cue’s hives drug apartcovers the Phase 2 results.
READ NEXT: Nvidia Is Becoming More Than a Chipmaker. Can it Sustain Its Exceptional Margins? and Vertiv vs. Eaton: Which AI Power Stock Offers More Cash Flow for the Price?





